A Norwegian study has indicated that the use of newer biological disease modifying anti-rheumatic drugs (DMARDs) can help reduce reduce cardiovascular disease (CVD) risk factors in patients with rheumatoid arthritis.
A new UK study has provided evidence that coronary heart disease and osteoporosis may share similar underlying causes.
Americas beverage companies are committed to being part of real solutions to public health challenges. This study does not show that consuming sugar-sweetened beverages causes chronic diseases and the authors themselves acknowledge that they are at best estimating effects of sugar-sweetened beverage consumption.
First Carotid Stent Indicated for Transcarotid Use and Optimized for Novel TransCarotid Artery Revascularization (TCAR) Procedure
Silk Road Medical has appointed Andrew Davis to the position of executive vice president of global pales. In this new role, Davis will assemble a sales organisation and lead the company’s commercialisation efforts for the transcarotid artery revascularisation (TCAR) procedure with the Enroute transcarotid neuroprotection system and the Enroute transcarotid stent system.
Philips has announced the launch of Ultrasound on Demand in the UK, an on-demand ultrasound solution which will go live on 1 June 2015.
The positive 30-day results from 120 patients out of a planned 240 patient cohort at high risk for endarterectomy, who underwent carotid artery stenting using the Wirion embolic protection device (Allium Medical), were published in EuroIntervention and presented at EuroPCR 2015 (19–22 May, Paris, France).
Royal Philips and Academic Medical Center (AMC) in Amsterdam, the Netherlands, have announced their collaboration in a European multicentre clinical study to investigate a new diagnostic technique targeting immediate assessment of the results of a minimally-invasive treatment for diabetic foot and critical limb ischaemia.
Penumbra has announced that the company’s ACE64 aspiration thrombectomy system received 510(k) marketing clearance from the US Food and Drug Administration for the revascularisation of large vessel occlusions in patients with acute ischaemic stroke.
InspireMD’s CGuard embolic prevention system has posted positive results in the PARADIGM study, led by principal investigator Piotr Musialek, as reported at the EuroPCR 2015 meeting (19–22 May, Paris, France).
Presented for the first time at EuroPCR 2015 (19–22 May, Paris, France) during the “Hot line” session on peripheral interventions, new clinical data from two different studies show that the IN.PACT Admiral drug-coated balloon from Medtronic successfully treated long lesions in the superficial femoral and popliteal arteries.
Shockwave Medical has announced US$40m in funding, co-led by returning investor Sofinnova Partners and new investor Venrock, with the participation of RA Capital, Deerfield, Sectoral Asset Management, Ally Bridge Group, and two undisclosed large-cap strategic investors.
Silk Road Medical has announced that the company has received premarket approval (PMA) from the US Food & Drug Administration (FDA) for the Enroute transcarotid stent system. The Enroute transcarotid stent is the first carotid stent that is introduced and implanted into the carotid artery through a direct common carotid access point to enable a safe and more direct approach to carotid artery stenting.
Nitiloop has received FDA clearance for its first product, NovaCross, which is intended to be used in conjunction with a guidewire to access discrete regions of the coronary or peripheral vasculature.
Delcath has announced that abstracts summarising the data from two European studies of treatment with the Delcath Hepatic Chemosat Delivery System will be presented at the upcoming Cardiovascular and Interventional Radiological Society of Europe (CIRSE) annual meeting (to be held in Lisbon, Portugal, 26–30 September).
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos